PCR's Pas de Deux

As it has for each of the past several years, much of the discussion at this year's Paris Course on Revascularization (PCR) centered on drug-eluting stents. From the latest results of the Taxus and Endeavor clinical trials to reports of the marketplace battle between Cypher and Taxus, drug-eluting stents are dominated by large companies. But we're only at the beginning of drug-eluting stents' technology race, and small companies, with innovative approaches to everything from delivery systems to fundamental biology, will increasingly make their voices heard as new technology comes out of the lab. And they're likely to use collaborations with others, particularly other start-ups, as a means of getting to market faster.

by David Cassak

As it has for each of the past several years, much of the discussion at this year's Paris Course on Revascularization (PCR) centered on drug-eluting stents. And, as in recent...

More from Archive

More from In Vivo

The 360 Degrees Of European Biotech Financing In 2025

 
• By 

Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.

Rising Leaders 2025: Pedro Valencia’s ADC Vision At AbbVie

 
• By 

From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.

Leaders At The Frontier: Conversations From SynBioBeta 2025

 
• By 

Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.